Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study - Cousin, Sophie; Blay, Jean‐Yves; Garcia, Irene Braña; Bono, Johann S.; Le Tourneau, Christophe; Moreno, Victor; Trigo, Jose; Hann, Christine L.; Azad, Arun A.; Im, Seock‐Ah; Cassier, Philippe A.; French, Christopher A.; et al. (International journal of cancer, 2022)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Antitumor activity; Appetite loss; Benzodiazepines - administration & dosage; Benzodiazepines - adverse effects; Benzodiazepines - pharmacokinetics; Benzodiazepines - therapeutic use; BET inhibitor; Bet protein; Breast cancer; Cancer; Castration; castration‐resistant prostate cancer; Estrogen receptors; Female; Gastrointestinal cancer; Gene expression; Gene set enrichment analysis; Humans; Lung cancer; Lung carcinoma; Male; Medical research; Middle Aged; molibresib; Nausea; Neoplasms - drug therapy; Nerve Tissue Proteins - antagonists & inhibitors; Nuclear Proteins - metabolism; NUT carcinoma; Patients; Pharmacodynamics; Pharmacokinetics; Prostate cancer; Proteins; Receptors, Cell Surface - antagonists & inhibitors; Safety; Small cell lung carcinoma; Solid tumors; Testicular Neoplasms - drug therapy; Thrombocytopenia; Young Adult; molibresib; BET inhibitor; castration-resistant prostate cancer; NUT carcinoma